<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902019000200246</article-id>
<article-id pub-id-type="doi">10.29262/ram.v66i2.625</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[De la investigación a la práctica: fases clínicas para el desarrollo de fármacos]]></article-title>
<article-title xml:lang="en"><![CDATA[From research to practice: clinical phases for drug development]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zurita-Cruz,]]></surname>
<given-names><![CDATA[Jessie Nallely]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barbosa-Cortés,]]></surname>
<given-names><![CDATA[Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villasís-Keever]]></surname>
<given-names><![CDATA[Miguel Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional Siglo XXI Hospital de Pediatría]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Unidad de Investigación en Análisis y Síntesis de la Evidencia ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>66</volume>
<numero>2</numero>
<fpage>246</fpage>
<lpage>253</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902019000200246&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902019000200246&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902019000200246&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Los ensayos clínicos toman gran relevancia en el desarrollo de nuevos fármacos al evaluar la farmacocinética, farmacodinamia, eficacia, seguridad y sus posibles efectos adversos. Para que un nuevo fármaco esté disponible para su uso cotidiano en pacientes, desde hace más de cuatro décadas se propuso un modelo que consiste en la realización de estudios de investigación secuenciales que se denominaron fases clínicas I, II, III y IV, las cuales se inician una vez que se han comprobado los efectos del fármaco en modelos celulares y animales (fase preclínica). En este artículo se sintetizan las características generales de cada una de las fases clínicas, pero además se describen las modificaciones que se han realizado en el trascurso de los años, a fin de disponer rápidamente de nuevos fármacos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Clinical trials become very relevant in the development of new drugs when their pharmacokinetics, pharmacodynamics, efficiency, safety and possible adverse effects are being assessed. So new drugs are available for their daily use in patients, a model has been proposed for more than four decades; This model consists in the realization of sequential research studies, which were called clinical phases I, II, III and IV, which begin once the drugs&#8217; effects have been verified in cellular and animal models (preclinical phase). In this article, the general characteristics of each of the clinical phases are synthesized but, apart from that, the modifications that have been done over the years are described with the purpose of making new drugs available in a quicker way.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Investigación clínica]]></kwd>
<kwd lng="es"><![CDATA[Ensayos clínicos]]></kwd>
<kwd lng="es"><![CDATA[Diseño de fármacos]]></kwd>
<kwd lng="en"><![CDATA[Clinical research]]></kwd>
<kwd lng="en"><![CDATA[Clinical trials]]></kwd>
<kwd lng="en"><![CDATA[Drug design]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Umscheid]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Margolis]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Grossman]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Key concepts of clinical trials: a narrative review]]></article-title>
<source><![CDATA[Postgrad Med]]></source>
<year>2011</year>
<volume>123</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>194-204</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Issa]]></surname>
<given-names><![CDATA[NT]]></given-names>
</name>
<name>
<surname><![CDATA[Wathieu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ojo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Byers]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Dakshanamurthy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug metabolism in preclinical drug development: a survey of the discovery process, toxicology, and computational tools]]></article-title>
<source><![CDATA[Curr Drug Metab]]></source>
<year>2017</year>
<volume>18</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>556-65</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Temple]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trials]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2000</year>
<volume>139</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>S133-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lazcano-Ponce]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar-Martínez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez-Castrellón]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Angeles-Llerenas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Garduño]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Viramontes]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized clinical trials: variants, randomization methods, analysis, ethical issues and regulations]]></article-title>
<source><![CDATA[Salud Publica Mex]]></source>
<year>2004</year>
<volume>46</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>559-84</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villasís-Keever]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El protocolo de investigación II: los diseños de estudio para investigación clínica]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Miranda-Novales]]></surname>
<given-names><![CDATA[MG.]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Alerg Mex]]></source>
<year>2016</year>
<volume>63</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>80-90</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kay]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Luke]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Tamer]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ASHP guidelines for the management of investigational drug products]]></article-title>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2018</year>
<volume>75</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>561-73</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ivy]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Siu]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Garrett-Mayer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rubinstein]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2010</year>
<volume>16</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1726-36</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coates]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Täubel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lorch]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practical risk management in early phase clinical trials]]></article-title>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2019</year>
<volume>75</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>483-96</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahipal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk and benefits of phase 1 clinical trial participation]]></article-title>
<source><![CDATA[Cancer Control]]></source>
<year>2014</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>193-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[EX]]></given-names>
</name>
<name>
<surname><![CDATA[Tannock]]></surname>
<given-names><![CDATA[IF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2004</year>
<volume>292</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2150-1</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety monitoring in clinical trials]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2013</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>94-106</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>International Conference on Harmonization. ICH harmonized tripartite guideline</collab>
<source><![CDATA[Guideline for good clinical practice E6(R1)]]></source>
<year>1996</year>
<publisher-name><![CDATA[International Conference on Harmonization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<source><![CDATA[Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Bélgica ]]></publisher-loc>
<publisher-name><![CDATA[European Commission]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>Committee for Medicinal Products for Human Use</collab>
<source><![CDATA[Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Inglaterra ]]></publisher-loc>
<publisher-name><![CDATA[Committee for Medicinal Products for Human Use]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kenter]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[AF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Establishing risk of human experimentation with drugs: lessons from TGN1412]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2006</year>
<volume>368</volume>
<numero>9544</numero>
<issue>9544</issue>
<page-range>1387-91</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lellouch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Explanatory and pragmatic attitudes in therapeutical trials]]></article-title>
<source><![CDATA[J Chronic Dis]]></source>
<year>2009</year>
<volume>6</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>499-505</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Treweek]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zwarenstein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Making trials matter: pragmatic and explanatory trials and the problem of applicability]]></article-title>
<source><![CDATA[Trials]]></source>
<year>2009</year>
<volume>10</volume>
<numero>37</numero>
<issue>37</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tuech]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Moutel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pessaux]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Thoma]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Schraub]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Herve]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Disclosure of competing financial interests and role of sponsors in phase III cancer trials]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2005</year>
<volume>41</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>2237-40</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<source><![CDATA[Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use]]></source>
<year></year>
<publisher-loc><![CDATA[Bélgica ]]></publisher-loc>
<publisher-name><![CDATA[European Commission]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<source><![CDATA[European Medicines Agency. Scientific guidance on post-authorization efficacy studies]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Países Bajos ]]></publisher-loc>
<publisher-name><![CDATA[European Medicines Agency]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gale]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Post-marketing studies of new insulins: sales or science?]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2012</year>
<volume>344</volume>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lasser]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Woolhandler]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Himmelstein]]></surname>
<given-names><![CDATA[DU]]></given-names>
</name>
<name>
<surname><![CDATA[Wolfe]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Bor]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Timing of new black box warnings and withdrawals for prescription medications]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2002</year>
<volume>287</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2215-20</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ye]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2016</year>
<volume>6</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suvarna]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase IV of drug development]]></article-title>
<source><![CDATA[Perspect Clin Res]]></source>
<year>2010</year>
<numero>1</numero>
<issue>1</issue>
<page-range>57-60</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Italiano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Massard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bahleda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vataire]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Deutsch]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Magné]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment outcome and survival in participants in phase 1 oncology trials carried out from 2003 to 2006 at Institute Gustave Roussy]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2008</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>787-92</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horstmann]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[McCabe]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Grochow]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Budd]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shoemaker]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risks and benefits of phase 1 oncology trials. 1991 through 2002]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2005</year>
<volume>352</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>895-904</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thall]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dose-finding based on efficacy-toxicity trade-offs]]></article-title>
<source><![CDATA[Biometrics]]></source>
<year>2004</year>
<volume>60</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>684-93</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ji]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bayesian dose finding in phase I/II clinical trials using toxicity and efficacy odds ratio]]></article-title>
<source><![CDATA[Biometrics]]></source>
<year>2006</year>
<volume>62</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>777-87</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wages]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Conaway]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase I/II adaptive design for drug combination oncology trials]]></article-title>
<source><![CDATA[Stat Med]]></source>
<year>2014</year>
<volume>33</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1990-2003</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braun]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The bivariate continual reassessment method. Extending the CRM to phase I trials of two competing outcomes]]></article-title>
<source><![CDATA[Control Clin Trials]]></source>
<year>2002</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>240-56</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Quigley]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Conaway]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extended model-based desings for more complex dose-finding studies]]></article-title>
<source><![CDATA[Stat Med]]></source>
<year>2011</year>
<volume>30</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2062-9</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wages]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Quigley]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Conaway]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase I design for completely for partially ordered treatment schedules]]></article-title>
<source><![CDATA[Stat Med]]></source>
<year>2014</year>
<volume>33</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>569-79</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mistry]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dunn]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Marshall]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines]]></article-title>
<source><![CDATA[BMC Med Res Methodol]]></source>
<year>2017</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>108</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bothwell]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Avorn]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[Kesselheim]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2018</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
